Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - Cingulate Inc. successfully closed a $12 million PIPE financing, indicating strong validation of its strategy and technology in the ADHD treatment market [1][2]. Financing Details - The PIPE financing was led by Falcon Creek Capital and completed at a price of $5.04 per share, with 80% warrant coverage [2][9]. - All investors in the PIPE financing are subject to a 180-day lock-up period, aligning long-term interests [3][9]. - The financing proceeds will support general operations and the commercial launch of CTx-1301, pending FDA approval [4][9]. Product Information - CTx-1301 is a once-daily, multi-core tablet designed to provide consistent symptom control for ADHD, utilizing Cingulate's Precision Timed Release™ platform [8][11]. - The FDA accepted Cingulate's NDA for CTx-1301 in October 2025, with a PDUFA target action date set for May 31, 2026 [9]. Company Overview - Cingulate Inc. focuses on developing next-generation pharmaceutical products for ADHD and other CNS disorders, leveraging its proprietary technology [11]. - The company is headquartered in Kansas City, Kansas, and aims to improve therapeutic outcomes for conditions with suboptimal treatment coverage [11]. Investor Relations - Falcon Creek Capital, a specialized investment firm, will designate up to two members to Cingulate's board, enhancing governance and strategic execution [4][12].